Hotchkis & Wiley Capital Management LLC boosted its position in shares of CVS Health Co. (NYSE:CVS - Free Report) by 34.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 11,897,034 shares of the pharmacy operator's stock after acquiring an additional 3,071,613 shares during the quarter. CVS Health accounts for 2.5% of Hotchkis & Wiley Capital Management LLC's portfolio, making the stock its 5th biggest holding. Hotchkis & Wiley Capital Management LLC owned 0.95% of CVS Health worth $748,085,000 at the end of the most recent reporting period.
A number of other hedge funds also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. bought a new position in CVS Health during the third quarter valued at approximately $25,000. Livelsberger Financial Advisory bought a new position in CVS Health during the third quarter valued at approximately $31,000. Reston Wealth Management LLC bought a new position in CVS Health during the third quarter valued at approximately $32,000. First Community Trust NA boosted its stake in CVS Health by 116.2% during the second quarter. First Community Trust NA now owns 562 shares of the pharmacy operator's stock valued at $33,000 after buying an additional 302 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new stake in shares of CVS Health in the 3rd quarter valued at approximately $33,000. Hedge funds and other institutional investors own 80.66% of the company's stock.
CVS Health Stock Up 0.2 %
Shares of CVS Health stock traded up $0.12 during trading on Tuesday, reaching $59.20. The company's stock had a trading volume of 9,006,999 shares, compared to its average volume of 11,305,876. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. The company has a market cap of $74.50 billion, a price-to-earnings ratio of 15.02, a P/E/G ratio of 1.01 and a beta of 0.54. CVS Health Co. has a 1-year low of $52.71 and a 1-year high of $83.25. The company has a 50-day simple moving average of $59.36 and a two-hundred day simple moving average of $58.77.
CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating analysts' consensus estimates of $1.08 by $0.01. CVS Health had a return on equity of 10.72% and a net margin of 1.36%. The business had revenue of $95.43 billion during the quarter, compared to analyst estimates of $92.72 billion. During the same quarter last year, the business posted $2.21 EPS. The company's revenue was up 6.3% on a year-over-year basis. As a group, equities analysts forecast that CVS Health Co. will post 5.37 earnings per share for the current year.
CVS Health Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Monday, October 21st were paid a dividend of $0.665 per share. The ex-dividend date was Monday, October 21st. This represents a $2.66 annualized dividend and a yield of 4.49%. CVS Health's dividend payout ratio (DPR) is currently 67.51%.
Analyst Upgrades and Downgrades
Several research firms have recently issued reports on CVS. Truist Financial reaffirmed a "buy" rating and issued a $67.00 price objective (down from $76.00) on shares of CVS Health in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised CVS Health from a "hold" rating to a "buy" rating and set a $66.00 price objective for the company in a research note on Tuesday. Evercore ISI increased their price target on CVS Health from $62.00 to $75.00 and gave the stock an "outperform" rating in a report on Tuesday, October 8th. Mizuho reduced their price target on CVS Health from $73.00 to $66.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. Finally, Wells Fargo & Company upgraded CVS Health from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $60.00 to $66.00 in a report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $70.50.
Read Our Latest Stock Report on CVS
CVS Health Company Profile
(
Free Report)
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
See Also
Before you consider CVS Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.
While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
